Clinical research

Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial)


Marcel Beijk
Marcel A. Beijk1*, MD; Franz-Josef Neumann2, MD; Marcus Wiemer3, MD; Eberhard Grube4, MD; Jürgen Haase5, MD PhD; Leif Thuesen6, MD; Christian Hamm7, MD; Susan Veldhof8, RN; Cecile Dorange8, MSc; Patrick W. Serruys9, MD, PhD; Jan J. Piek1, MD, PhD
1. Academic Medical Center, Amsterdam, The Netherlands; 2. Herzzentrum, Bad Krozingen, Germany; 3. Herzzentrum, Bad Oeynhausen, Germany; 4. HELIOS Heart Center Siegburg, Siegburg, Germany; 5. Red Cross Hospital, Frankfurt, Germany; 6. Skejby Sygehus, Aarh

Aims: The successful use of everolimus on a durable polymer was earlier reported with 6 and 12 months data from this first-in-man study. This reports the long-term follow-up of the XIENCE V

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Safety and efficacy of multiple, overlapping polymer-based paclitaxel-eluting stents

Latest news